MAP2K7 and chronic myelogenous leukemia, BCR-ABL1 positive: CK2-inhibition by CX-5011 induces cell death by apoptosis and acts synergistically with imatinib or the MEK-inhibitor U0126 in reducing the viability of imatinib-resistant CML cells.